These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 28406714)
1. Clinical Outcomes Associated with Achromobacter Species Infection in Patients with Cystic Fibrosis. Somayaji R; Stanojevic S; Tullis DE; Stephenson AL; Ratjen F; Waters V Ann Am Thorac Soc; 2017 Sep; 14(9):1412-1418. PubMed ID: 28406714 [TBL] [Abstract][Full Text] [Related]
2. Prevalence and Outcomes of Achromobacter Species Infections in Adults with Cystic Fibrosis: a North American Cohort Study. Edwards BD; Greysson-Wong J; Somayaji R; Waddell B; Whelan FJ; Storey DG; Rabin HR; Surette MG; Parkins MD J Clin Microbiol; 2017 Jul; 55(7):2074-2085. PubMed ID: 28446570 [No Abstract] [Full Text] [Related]
3. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. Waters V; Atenafu EG; Lu A; Yau Y; Tullis E; Ratjen F J Cyst Fibros; 2013 Sep; 12(5):482-6. PubMed ID: 23294530 [TBL] [Abstract][Full Text] [Related]
4. Effect of respiratory Achromobacter spp. infection on pulmonary function in patients with cystic fibrosis. Recio R; Brañas P; Martínez MT; Chaves F; Orellana MA J Med Microbiol; 2018 Jul; 67(7):952-956. PubMed ID: 29787364 [TBL] [Abstract][Full Text] [Related]
5. Pan-Resistant Achromobacter xylosoxidans and Stenotrophomonas maltophilia Infection in Cystic Fibrosis Does Not Reduce Survival After Lung Transplantation. Lobo LJ; Tulu Z; Aris RM; Noone PG Transplantation; 2015 Oct; 99(10):2196-202. PubMed ID: 25856407 [TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes Associated with Somayaji R; Yau YCW; Tullis E; LiPuma JJ; Ratjen F; Waters V Ann Am Thorac Soc; 2020 Dec; 17(12):1542-1548. PubMed ID: 32678679 [No Abstract] [Full Text] [Related]
7. Uncovering Differences in Virulence Markers Associated with Achromobacter Species of CF and Non-CF Origin. Filipic B; Malesevic M; Vasiljevic Z; Lukic J; Novovic K; Kojic M; Jovcic B Front Cell Infect Microbiol; 2017; 7():224. PubMed ID: 28611955 [No Abstract] [Full Text] [Related]
8. Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV Ramos KJ; Quon BS; Heltshe SL; Mayer-Hamblett N; Lease ED; Aitken ML; Weiss NS; Goss CH Chest; 2017 Jun; 151(6):1320-1328. PubMed ID: 28115168 [TBL] [Abstract][Full Text] [Related]
9. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. de Boer K; Vandemheen KL; Tullis E; Doucette S; Fergusson D; Freitag A; Paterson N; Jackson M; Lougheed MD; Kumar V; Aaron SD Thorax; 2011 Aug; 66(8):680-5. PubMed ID: 21680566 [TBL] [Abstract][Full Text] [Related]
10. Achromobacter species in cystic fibrosis: cross-infection caused by indirect patient-to-patient contact. Hansen CR; Pressler T; Ridderberg W; Johansen HK; Skov M J Cyst Fibros; 2013 Dec; 12(6):609-15. PubMed ID: 23769270 [TBL] [Abstract][Full Text] [Related]
11. Clinical impact of Achromobacter xylosoxidans colonization/infection in patients with cystic fibrosis. Firmida MC; Pereira RH; Silva EA; Marques EA; Lopes AJ Braz J Med Biol Res; 2016; 49(4):e5097. PubMed ID: 26909788 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes associated with Achromobacter species infection in people with cystic fibrosis. Kerem E; Orenti A; Zolin A; Annicchiarico L; Drevinek P; J Cyst Fibros; 2023 Mar; 22(2):334-343. PubMed ID: 36418214 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain. Barrado L; Brañas P; Orellana MÁ; Martínez MT; García G; Otero JR; Chaves F J Clin Microbiol; 2013 Jun; 51(6):1927-30. PubMed ID: 23536401 [TBL] [Abstract][Full Text] [Related]
14. Achromobacter spp. prevalence and adaptation in cystic fibrosis lung infection. Veschetti L; Boaretti M; Saitta GM; Passarelli Mantovani R; Lleò MM; Sandri A; Malerba G Microbiol Res; 2022 Oct; 263():127140. PubMed ID: 35931003 [TBL] [Abstract][Full Text] [Related]
15. Impact of High Diversity of Achromobacter Populations within Cystic Fibrosis Sputum Samples on Antimicrobial Susceptibility Testing. Dupont C; Jumas-Bilak E; Michon AL; Chiron R; Marchandin H J Clin Microbiol; 2017 Jan; 55(1):206-215. PubMed ID: 27807149 [TBL] [Abstract][Full Text] [Related]
16. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. Wang M; Ridderberg W; Hansen CR; Høiby N; Jensen-Fangel S; Olesen HV; Skov M; Lemming LE; Pressler T; Johansen HK; Nørskov-Lauritsen N J Cyst Fibros; 2013 Dec; 12(6):638-43. PubMed ID: 23727271 [TBL] [Abstract][Full Text] [Related]
17. Factors influencing the acquisition of Stenotrophomonas maltophilia infection in cystic fibrosis patients. Stanojevic S; Ratjen F; Stephens D; Lu A; Yau Y; Tullis E; Waters V J Cyst Fibros; 2013 Dec; 12(6):575-83. PubMed ID: 23757360 [TBL] [Abstract][Full Text] [Related]